Compare MLCI & BHST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MLCI | BHST |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.0M | 108.6M |
| IPO Year | N/A | N/A |
| Metric | MLCI | BHST |
|---|---|---|
| Price | $5.84 | $4.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 88.0K | 31.9K |
| Earning Date | 03-13-2026 | 03-30-2026 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $104,823,000.00 | $32,720,000.00 |
| Revenue This Year | N/A | $116.40 |
| Revenue Next Year | N/A | $55.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 63.13 | 45.88 |
| 52 Week Low | $5.78 | $4.65 |
| 52 Week High | $8.75 | $12.80 |
| Indicator | MLCI | BHST |
|---|---|---|
| Relative Strength Index (RSI) | 16.74 | 44.89 |
| Support Level | $6.00 | $4.82 |
| Resistance Level | $8.31 | $5.04 |
| Average True Range (ATR) | 0.36 | 0.32 |
| MACD | -0.24 | 0.03 |
| Stochastic Oscillator | 2.77 | 25.00 |
Mount Logan Capital Inc operates as emerging asset management and investment firm focused on investing in public and private debt securities in the North American market. The Company's reporting segments include asset management and insurance. The asset management segment reflects the Company's historical operations through its subsidiaries, including ML Management, and the insurance segment represents Ability's operations. The Company through its subsidiaries, earns management and incentive fees and servicing fees for providing investment management, monitoring and other services to investment vehicles and advisers. The insurance business is operated by Ability. Ability's insurance business consists of premium revenue from long term care insurance policies.
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.